-
2
-
-
6044247223
-
The evolving treatment of chronic hepatitis C: Where we stand a decade out
-
15468610
-
The evolving treatment of chronic hepatitis C: where we stand a decade out. Saadeh S Davis GL, Cleve Clin J Med 2004 71 Suppl 3 3 7 15468610
-
(2004)
Cleve Clin J Med
, vol.71
, Issue.SUPPL. 3
, pp. 193-197
-
-
Saadeh, S.1
Davis, G.L.2
-
3
-
-
33748757526
-
Human schistosomiasis
-
DOI 10.1016/S0140-6736(06)69440-3, PII S0140673606694403
-
Human schistosomiasis. Gryseels B Polman K, Clerinx J Kestens L, Lancet 2006 368 1106 1118 10.1016/S0140-6736(06)69440-3 16997665 (Pubitemid 44402679)
-
(2006)
Lancet
, vol.368
, Issue.9541
, pp. 1106-1118
-
-
Gryseels, B.1
Polman, K.2
Clerinx, J.3
Kestens, L.4
-
4
-
-
76149141825
-
Hepatitis C virus: Molecular biology & current therapeutic options
-
20167971
-
Hepatitis C virus: molecular biology & current therapeutic options. Sharma SD, Indian J Med Res 2010 131 17 34 20167971
-
(2010)
Indian J Med Res
, vol.131
, pp. 17-34
-
-
Sharma, S.D.1
-
5
-
-
84859769302
-
Global Alert and Response (GAR), Hepatitis C
-
Global Alert and Response (GAR), Hepatitis C. World Health Organization 2002
-
(2002)
World Health Organization
-
-
-
6
-
-
74749100404
-
Interferon therapy of hepatitis C: Molecular insights into success and failure
-
19950038
-
Interferon therapy of hepatitis C: molecular insights into success and failure. Sarasin-Filipowicz M, Swiss Med Wkly 2010 140 3 11 19950038
-
(2010)
Swiss Med Wkly
, vol.140
, pp. 3-11
-
-
Sarasin-Filipowicz, M.1
-
8
-
-
33749259433
-
Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment
-
Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment. Caruntu FA Benea L, J Gastrointestin Liver Dis 2006 15 249 256 17013450 (Pubitemid 44483093)
-
(2006)
Journal of Gastrointestinal and Liver Diseases
, vol.15
, Issue.3
, pp. 249-256
-
-
Caruntu, F.A.1
Benea, L.2
-
10
-
-
0037133079
-
Surprisingly small effect of antiviral treatment in patients with hepatitis C
-
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Falck-Ytter Y Kale H, Mullen KD Sarbah SA, Sorescu L McCullough AJ, Ann Intern Med 2002 136 288 292 11848726 (Pubitemid 34150758)
-
(2002)
Annals of Internal Medicine
, vol.136
, Issue.4
, pp. 288-292
-
-
Falck-Ytter, Y.1
Kale, H.2
Mullen, K.D.3
Sarbah, S.A.4
Sorescu, L.5
McCullough, A.J.6
-
11
-
-
77955359911
-
Treatment of hepatitis C in children: A systematic review
-
10.1371/journal.pone.0011542. 20644626
-
Treatment of hepatitis C in children: a systematic review. Hu J Doucette K Hartling L Tjosvold L, Robinson J,, PLoS One 2010 5 11542 10.1371/journal. pone.0011542 20644626
-
(2010)
PLoS One
, vol.5
, pp. 511542
-
-
Hu, J.1
Doucette, K.2
Hartling, L.3
Tjosvold, L.4
Robinson, J.5
-
12
-
-
77954774460
-
Managing HCV infection in pediatric age group: Suggested recommendations
-
10.4103/1319-3767.65182. 20616426
-
Managing HCV infection in pediatric age group: suggested recommendations. Danish FA Koul SS Subhani FR Rabbani AE, Yasmin S,, Saudi J Gastroenterol 2010 16 230 235 10.4103/1319-3767.65182 20616426
-
(2010)
Saudi J Gastroenterol
, vol.16
, pp. 230-235
-
-
Danish, F.A.1
Koul, S.S.2
Subhani, F.R.3
Rabbani, A.E.4
Yasmin, S.5
-
13
-
-
1242340436
-
Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life
-
DOI 10.1136/gut.2003.027581
-
Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Hickman IJ Jonsson JR Prins JB Ash S, Purdie DM Clouston AD, Powell EE,, Gut 2004 53 413 419 10.1136/gut.2003.027581 14960526 (Pubitemid 38241340)
-
(2004)
Gut
, vol.53
, Issue.3
, pp. 413-419
-
-
Hickman, I.J.1
Jonsson, J.R.2
Prins, J.B.3
Ash, S.4
Purdie, D.M.5
Clouston, A.D.6
Powell, E.E.7
-
14
-
-
0032924020
-
Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis
-
Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hourigan LF Macdonald GA Purdie D Whitehall VH, Shorthouse C Clouston A, Powell EE,, Hepatology 1999 29 1215 1219 10.1002/hep.510290401 10094967 (Pubitemid 29168757)
-
(1999)
Hepatology
, vol.29
, Issue.4
, pp. 1215-1219
-
-
Hourigan, L.F.1
Macdonald, G.A.2
Purdie, D.3
Whitehall, V.H.4
Shorthouse, C.5
Clouston, A.6
Powell, E.E.7
-
15
-
-
77954281477
-
Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis
-
20386865
-
Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis. Mas VR Fassnacht R, Archer KJ Maluf D, Mol Med 2010 16 287 297 20386865
-
(2010)
Mol Med
, vol.16
, pp. 287-297
-
-
Mas, V.R.1
Fassnacht, R.2
Archer, K.J.3
Maluf, D.4
-
16
-
-
77950827009
-
Impact of alcohol on hepatitis C virus replication and interferon signaling
-
10.3748/wjg.v16.i11.1337. 20238400
-
Impact of alcohol on hepatitis C virus replication and interferon signaling. McCartney EM Beard MR, World J Gastroenterol 2010 16 1337 1343 10.3748/wjg.v16.i11.1337 20238400
-
(2010)
World J Gastroenterol
, vol.16
, pp. 1337-1343
-
-
McCartney, E.M.1
Beard, M.R.2
-
17
-
-
33644844121
-
The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma
-
DOI 10.1038/sj.bjc.6602981, PII 6602981
-
The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma. Fujita Y Shibata A Ogimoto I Kurozawa Y, Nose T Yoshimura T, Suzuki H Iwai N, Sakata R Ichikawa S, Tamakoshi A,, Br J Cancer 2006 94 737 739 16465190 (Pubitemid 43361907)
-
(2006)
British Journal of Cancer
, vol.94
, Issue.5
, pp. 737-739
-
-
Fujita, Y.1
Shibata, A.2
Ogimoto, I.3
Kurozawa, Y.4
Nose, T.5
Yoshimura, T.6
Suzuki, H.7
Iwai, N.8
Sakata, R.9
Ichikawa, S.10
Tamakoshi, A.11
-
18
-
-
58149196181
-
Symptomatic acute hepatitis C in Egypt: Diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a
-
10.1371/journal.pone.0004085. 19115010
-
Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a. Sharaf Eldin N Ismail S, Mansour H Rekacewicz C, El-Houssinie M El-Kafrawy S, El Aidi S Abdel-Hamid M, Esmat G Pol S, Fontanet A Mohamed MK, PLoS One 2008 3 4085 10.1371/journal.pone.0004085 19115010
-
(2008)
PLoS One
, vol.3
, pp. 54085
-
-
Sharaf Eldin, N.1
Ismail, S.2
Mansour, H.3
Rekacewicz, C.4
El-Houssinie, M.5
El-Kafrawy, S.6
El Aidi, S.7
Abdel-Hamid, M.8
Esmat, G.9
Pol, S.10
Fontanet, A.11
Mohamed, M.K.12
-
19
-
-
33644857481
-
Peginterferon alfa-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response
-
DOI 10.1053/j.gastro.2006.01.034, PII S0016508506000618
-
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Kamal SM Fouly AE Kamel RR Hockenjos B, Al Tawil A Khalifa KE, He Q Koziel MJ, El Naggar KM Rasenack J, Afdhal NH,, Gastroenterology 2006 130 632 638 10.1053/j.gastro.2006.01.034 16530503 (Pubitemid 43374512)
-
(2006)
Gastroenterology
, vol.130
, Issue.3
, pp. 632-638
-
-
Kamal, S.M.1
Fouly, A.E.2
Kamel, R.R.3
Hockenjos, B.4
Al Tawil, A.5
Khalifa, K.E.6
He, Q.7
Koziel, M.J.8
El Naggar, K.M.9
Rasenack, J.10
Afdhal, N.H.11
-
20
-
-
0038575483
-
Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance
-
DOI 10.1016/S0016-5085(03)00668-1
-
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gerlach JT Diepolder HM Zachoval R Gruener NH, Jung MC Ulsenheimer A, Schraut WW Schirren CA, Waechtler M Backmund M, Pape GR,, Gastroenterology 2003 125 80 88 10.1016/S0016-5085(03)00668-1 12851873 (Pubitemid 36799109)
-
(2003)
Gastroenterology
, vol.125
, Issue.1
, pp. 80-88
-
-
Gerlach, J.T.1
Diepolder, H.M.2
Zachoval, R.3
Gruener, N.H.4
Jung, M.-C.5
Ulsenheimer, A.6
Schraut, W.W.7
Schirren, C.A.8
Waechtler, M.9
Backmund, M.10
Pape, G.R.11
-
22
-
-
0034619946
-
Peginterferon alfa-2a in patients with chronic hepatitis C
-
10.1056/NEJM200012073432301. 11106715
-
Peginterferon alfa-2a in patients with chronic hepatitis C. Zeuzem S Feinman SV, Rasenack J Heathcote EJ, Lai MY Gane E, O'Grady J Reichen J, Diago M Lin A, Hoffman J Brunda MJ, N Engl J Med 2000 343 1666 1672 10.1056/NEJM200012073432301 11106715
-
(2000)
N Engl J Med
, vol.343
, pp. 1666-1672
-
-
Zeuzem, S.1
Feinman, S.V.2
Rasenack, J.3
Heathcote, E.J.4
Lai, M.Y.5
Gane, E.6
O'Grady, J.7
Reichen, J.8
Diago, M.9
Lin, A.10
Hoffman, J.11
Brunda, M.J.12
-
23
-
-
41149086703
-
Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: A randomised study
-
17881538
-
Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Liu CH Liang CC Lin JW Chen SI, Tsai HB Chang CS, Hung PH Kao JH, Liu CJ Lai MY, Chen JH Chen PJ, Chen DS,, Gut 2008 57 525 530 17881538
-
(2008)
Gut
, vol.57
, pp. 525-530
-
-
Liu, C.H.1
Liang, C.C.2
Lin, J.W.3
Chen, S.I.4
Tsai, H.B.5
Chang, C.S.6
Hung, P.H.7
Kao, J.H.8
Liu, C.J.9
Lai, M.Y.10
Chen, J.H.11
Chen, P.J.12
Chen, D.S.13
-
24
-
-
0034619980
-
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
-
10.1056/NEJM200012073432302. 11106716
-
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. Heathcote EJ Shiffman ML, Cooksley WG Dusheiko GM, Lee SS Balart L, Reindollar R Reddy RK, Wright TL Lin A, Hoffman J De Pamphilis J, N Engl J Med 2000 343 1673 1680 10.1056/NEJM200012073432302 11106716
-
(2000)
N Engl J Med
, vol.343
, pp. 1673-1680
-
-
Heathcote, E.J.1
Shiffman, M.L.2
Cooksley, W.G.3
Dusheiko, G.M.4
Lee, S.S.5
Balart, L.6
Reindollar, R.7
Reddy, R.K.8
Wright, T.L.9
Lin, A.10
Hoffman, J.11
De Pamphilis, J.12
-
25
-
-
33745713376
-
A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)
-
10.1016/j.jhep.2006.03.008. 16780997
-
A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). Silva M Poo J, Wagner F Jackson M, Cutler D Grace M, Bordens R Cullen C, Harvey J Laughlin M, J Hepatol 2006 45 204 213 10.1016/j.jhep.2006.03.008 16780997
-
(2006)
J Hepatol
, vol.45
, pp. 204-213
-
-
Silva, M.1
Poo, J.2
Wagner, F.3
Jackson, M.4
Cutler, D.5
Grace, M.6
Bordens, R.7
Cullen, C.8
Harvey, J.9
Laughlin, M.10
-
26
-
-
65749093081
-
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients
-
10.1093/jac/dkp106. 19363085
-
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. Berenguer J Gonzalez-Garcia J Lopez-Aldeguer J Von-Wichmann MA, Quereda C Hernando A, Sanz J Tural C, Ortega E Mallolas J, Santos I Miralles P, Montes ML Bellon JM, Esteban H,, J Antimicrob Chemother 2009 63 1256 1263 10.1093/jac/dkp106 19363085
-
(2009)
J Antimicrob Chemother
, vol.63
, pp. 1256-1263
-
-
Berenguer, J.1
Gonzalez-Garcia, J.2
Lopez-Aldeguer, J.3
Von-Wichmann, M.A.4
Quereda, C.5
Hernando, A.6
Sanz, J.7
Tural, C.8
Ortega, E.9
Mallolas, J.10
Santos, I.11
Miralles, P.12
Montes, M.L.13
Bellon, J.M.14
Esteban, H.15
-
27
-
-
0034532953
-
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
-
DOI 10.1038/82191
-
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Crotty S Maag D, Arnold JJ Zhong W, Lau JY Hong Z, Andino R Cameron CE, Nat Med 2000 6 1375 1379 10.1038/82191 11100123 (Pubitemid 32001022)
-
(2000)
Nature Medicine
, vol.6
, Issue.12
, pp. 1375-1379
-
-
Crotty, S.1
Maag, D.2
Arnold, J.J.3
Zhong, W.4
Lau, J.Y.N.5
Hong, Z.6
Andino, R.7
Cameron, C.E.8
-
28
-
-
13744258758
-
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase
-
DOI 10.1128/JVI.79.3.1943-1947.2005
-
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. Leyssen P Balzarini J, De Clercq E Neyts J, J Virol 2005 79 1943 1947 10.1128/JVI.79.3.1943-1947.2005 15650220 (Pubitemid 40459141)
-
(2005)
Journal of Virology
, vol.79
, Issue.3
, pp. 1943-1947
-
-
Leyssen, P.1
Balzarini, J.2
De Clercq, E.3
Neyts, J.4
-
29
-
-
0028825313
-
Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
-
7486483
-
Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Di Bisceglie AM Conjeevaram HS, Fried MW Sallie R, Park Y Yurdaydin C, Swain M Kleiner DE, Mahaney K Hoofnagle JH, Ann Intern Med 1995 123 897 903 7486483
-
(1995)
Ann Intern Med
, vol.123
, pp. 897-903
-
-
Di Bisceglie, A.M.1
Conjeevaram, H.S.2
Fried, M.W.3
Sallie, R.4
Park, Y.5
Yurdaydin, C.6
Swain, M.7
Kleiner, D.E.8
Mahaney, K.9
Hoofnagle, J.H.10
-
30
-
-
10344259671
-
Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
-
DOI 10.1016/S0168-8278(96)80225-X
-
Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. Dusheiko G Main J, Thomas H Reichard O, Lee C Dhillon A, Rassam S Fryden A, Reesink H Bassendine M, Norkrans G Cuypers T, Lelie N Telfer P, Watson J Weegink C, Sillikens P Weiland O, J Hepatol 1996 25 591 598 10.1016/S0168-8278(96)80225-X 8938532 (Pubitemid 26373872)
-
(1996)
Journal of Hepatology
, vol.25
, Issue.5
, pp. 591-598
-
-
Dusheiko, G.1
Main, J.2
Thomas, H.3
Reichard, O.4
Lee, C.5
Dhillon, A.6
Rassam, S.7
Fryden, A.8
Reesink, H.9
Bassendine, M.10
Norkrans, G.11
Cuypers, T.12
Lelie, N.13
Telfer, P.14
Watson, J.15
Weegink, C.16
Sillikens, P.17
Weiland, O.18
-
31
-
-
0030227143
-
Prolonged therapy of chronic hepatitis C with ribavirin
-
Prolonged therapy of chronic hepatitis C with ribavirin. Hoofnagle JH Lau D Conjeevaram H Kleiner D, Di Bisceglie AM,, J Viral Hepat 1996 3 247 252 10.1111/j.1365-2893.1996.tb00050.x 8914004 (Pubitemid 126733924)
-
(1996)
Journal of Viral Hepatitis
, vol.3
, Issue.5
, pp. 247-252
-
-
Hoofnagle, J.H.1
Lau, D.2
Conjeevaram, H.3
Kleiner, D.4
Di Bisceglie, A.M.5
-
32
-
-
59149106172
-
What future for ribavirin?
-
19207968
-
What future for ribavirin? Shiffman ML, Liver Int 2009 29 Suppl 1 68 73 19207968
-
(2009)
Liver Int
, vol.29
, Issue.SUPPL. 1
, pp. 68-73
-
-
Shiffman, M.L.1
-
33
-
-
30044432484
-
American gastroenterological association technical review on the management of hepatitis C
-
DOI 10.1053/j.gastro.2005.11.010, PII S0016508505022705
-
American Gastroenterological Association technical review on the management of hepatitis C. Dienstag JL McHutchison JG, Gastroenterology 2006 130 231 264 quiz 214-237 10.1053/j.gastro.2005.11.010 16401486 (Pubitemid 43049856)
-
(2006)
Gastroenterology
, vol.130
, Issue.1
, pp. 231-264
-
-
Dienstag, J.L.1
Mchutchison, J.G.2
-
34
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
DOI 10.1016/S0140-6736(01)06102-5
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Manns MP McHutchison JG, Gordon SC Rustgi VK, Shiffman M Reindollar R, Goodman ZD Koury K, Ling M Albrecht JK, Lancet 2001 358 958 965 10.1016/S0140-6736(01) 06102-5 11583749 (Pubitemid 32913521)
-
(2001)
Lancet
, vol.358
, Issue.9286
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
Goodman, Z.D.7
Koury, K.8
Ling, M.-H.9
Albrecht, J.K.10
-
35
-
-
1542378867
-
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
-
14996676
-
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Hadziyannis SJ Sette H Jr, Morgan TR Balan V, Diago M Marcellin P, Ramadori G Bodenheimer H Jr, Bernstein D Rizzetto M, Zeuzem S Pockros PJ, Lin A Ackrill AM, Ann Intern Med 2004 140 346 355 14996676
-
(2004)
Ann Intern Med
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette, Jr.H.2
Morgan, T.R.3
Balan, V.4
Diago, M.5
Marcellin, P.6
Ramadori, G.7
Bodenheimer, Jr.H.8
Bernstein, D.9
Rizzetto, M.10
Zeuzem, S.11
Pockros, P.J.12
Lin, A.13
Ackrill, A.M.14
-
36
-
-
77950624679
-
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C
-
10.1002/hep.23489. 20162613
-
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Petta S Camma C Scazzone C Tripodo C, Di Marco V Bono A, Cabibi D Licata G, Porcasi R Marchesini G, Craxi A,, Hepatology 2010 51 1158 1167 10.1002/hep.23489 20162613
-
(2010)
Hepatology
, vol.51
, pp. 1158-1167
-
-
Petta, S.1
Camma, C.2
Scazzone, C.3
Tripodo, C.4
Di Marco, V.5
Bono, A.6
Cabibi, D.7
Licata, G.8
Porcasi, R.9
Marchesini, G.10
Craxi, A.11
-
38
-
-
0036784356
-
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
-
10.1016/S0168-8278(02)00211-8. 12217604
-
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). Lee SS Heathcote EJ Reddy KR Zeuzem S, Fried MW Wright TL, Pockros PJ Haussinger D, Smith CI Lin A, Pappas SC,, J Hepatol 2002 37 500 506 10.1016/S0168-8278(02)00211-8 12217604
-
(2002)
J Hepatol
, vol.37
, pp. 500-506
-
-
Lee, S.S.1
Heathcote, E.J.2
Reddy, K.3
Zeuzem, R.S.4
Fried, M.W.5
Wright, T.L.6
Pockros, P.7
Haussinger, J.D.8
Smith, C.9
Lin, I.A.10
Pappas, S.C.11
-
39
-
-
23444460553
-
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
-
DOI 10.1016/j.jhep.2005.04.009, PII S016882780500320X
-
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. Ferenci P Fried MW Shiffman ML Smith CI, Marinos G Goncales FL Jr, Haussinger D Diago M, Carosi G Dhumeaux D, Craxi A Chaneac M, Reddy KR,, J Hepatol 2005 43 425 433 10.1016/j.jhep.2005.04.009 15990196 (Pubitemid 41111423)
-
(2005)
Journal of Hepatology
, vol.43
, Issue.3
, pp. 425-433
-
-
Ferenci, P.1
Fried, M.W.2
Shiffman, M.L.3
Smith, C.I.4
Marinos, G.5
Goncales Jr., F.L.6
Haussinger, D.7
Diago, M.8
Carosi, G.9
Dhumeaux, D.10
Craxi, A.11
Chaneac, M.12
Reddy, K.R.13
-
40
-
-
0036378296
-
Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C
-
10.1046/j.1365-2893.2002.00376.x. 12225327
-
Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. Layden TJ Layden JE, Reddy KR Levy-Drummer RS, Poulakos J Neumann AU, J Viral Hepat 2002 9 334 339 10.1046/j.1365-2893.2002.00376.x 12225327
-
(2002)
J Viral Hepat
, vol.9
, pp. 334-339
-
-
Layden, T.J.1
Layden, J.E.2
Reddy, K.R.3
Levy-Drummer, R.S.4
Poulakos, J.5
Neumann, A.U.6
-
41
-
-
74049136040
-
Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population
-
10.1111/j.1365-2893.2009.01157.x. 19674282
-
Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. Rodriguez-Torres M Sulkowski MS Chung RT Hamzeh FM, Jensen DM,, J Viral Hepat 2010 17 139 147 10.1111/j.1365-2893.2009.01157.x 19674282
-
(2010)
J Viral Hepat
, vol.17
, pp. 139-147
-
-
Rodriguez-Torres, M.1
Sulkowski, M.S.2
Chung, R.T.3
Hamzeh, F.M.4
Jensen, D.M.5
-
42
-
-
84859770543
-
High sustained virologic response (SVR) among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir (BOC) plus peginterferon alfa-2a/ribavirin
-
Berlin, Germany. 22139868
-
High sustained virologic response (SVR) among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir (BOC) plus peginterferon alfa-2a/ribavirin. Flamm S Lawitz E, Jacobson I Rubin R, Bourliere M Hezode C, Vierling J Niederau C, Sherman M Goteti V, Vilchez R Brass C, Albrecht J Poordad F, The International Liver Congress 2011 by EASL (46th annual meeting) Berlin, Germany 2011 22139868
-
(2011)
The International Liver Congress 2011 by EASL (46th Annual Meeting)
-
-
Flamm, S.1
Lawitz, E.2
Jacobson, I.3
Rubin, R.4
Bourliere, M.5
Hezode, C.6
Vierling, J.7
Niederau, C.8
Sherman, M.9
Goteti, V.10
Vilchez, R.11
Brass, C.12
Albrecht, J.13
Poordad, F.14
-
43
-
-
84859769304
-
Telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ribavirin
-
Berlin, Germany. 22139868
-
Telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ribavirin. Zeuzem S Andreone P Pol S Lawitz EJ, Diago M Roberts S, Focaccia R Younossi ZM, Foster GR Horban APPJ, Van Heeswijk R de Meyer S, Luo S Picchio G, Beumont M,, The International Liver Congress 2011 by EASL (46th annual meeting) Berlin, Germany 2011 22139868
-
(2011)
The International Liver Congress 2011 by EASL (46th Annual Meeting)
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
Lawitz, E.J.4
Diago, M.5
Roberts, S.6
Focaccia, R.7
Younossi, Z.M.8
Foster, G.R.9
Horban, A.P.P.J.10
Van Heeswijk11
De Meyer, R.S.12
Luo, S.13
Picchio, G.14
Beumont, M.15
-
44
-
-
84859744756
-
Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial
-
Berlin, Germany. 22139868
-
Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. Jacobson IM Catlett I Marcellin P Bzowej NH, Muir AJ Adda N, Bengtsson L George S, Seepersaud S Ramachandran R, Sussky K Kauffman RS, Botfield M,, The International Liver Congress 2011 by EASL (46th annual meeting) Berlin, Germany 2011 22139868
-
(2011)
The International Liver Congress 2011 by EASL (46th Annual Meeting)
-
-
Jacobson, I.M.1
Catlett, I.2
Marcellin, P.3
Bzowej, N.H.4
Muir, A.J.5
Adda, N.6
Bengtsson, L.7
George, S.8
Seepersaud, S.9
Ramachandran, R.10
Sussky, K.11
Kauffman, R.S.12
Botfield, M.13
-
45
-
-
34247565001
-
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
-
DOI 10.1002/hep.21774
-
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Forestier N Reesink HW Weegink CJ McNair L, Kieffer TL Chu HM, Purdy S Jansen PL, Zeuzem S,, Hepatology 2007 46 640 648 10.1002/hep.21774 17879366 (Pubitemid 47436108)
-
(2007)
Hepatology
, vol.46
, Issue.3
, pp. 640-648
-
-
Forestier, N.1
Reesink, H.W.2
Weegink, C.J.3
McNair, L.4
Kieffer, T.L.5
Chu, H.-M.6
Purdy, S.7
Jansen, P.L.M.8
Zeuzem, S.9
-
46
-
-
65449171953
-
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
-
10.1056/NEJMoa0807650. 19403903
-
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. Hezode C Forestier N, Dusheiko G Ferenci P, Pol S Goeser T, Bronowicki JP Bourliere M, Gharakhanian S Bengtsson L, McNair L George S, Kieffer T Kwong A, Kauffman RS Alam J, Pawlotsky JM Zeuzem S, N Engl J Med 2009 360 1839 1850 10.1056/NEJMoa0807650 19403903
-
(2009)
N Engl J Med
, vol.360
, pp. 1839-1850
-
-
Hezode, C.1
Forestier, N.2
Dusheiko, G.3
Ferenci, P.4
Pol, S.5
Goeser, T.6
Bronowicki, J.P.7
Bourliere, M.8
Gharakhanian, S.9
Bengtsson, L.10
McNair, L.11
George, S.12
Kieffer, T.13
Kwong, A.14
Kauffman, R.S.15
Alam, J.16
Pawlotsky, J.M.17
Zeuzem, S.18
-
47
-
-
65449152185
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
-
10.1056/NEJMoa0806104. 19403902
-
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. McHutchison JG Everson GT Gordon SC Jacobson IM, Sulkowski M Kauffman R, McNair L Alam J, Muir AJ,, N Engl J Med 2009 360 1827 1838 10.1056/NEJMoa0806104 19403902
-
(2009)
N Engl J Med
, vol.360
, pp. 1827-1838
-
-
McHutchison, J.G.1
Everson, G.T.2
Gordon, S.C.3
Jacobson, I.M.4
Sulkowski, M.5
Kauffman, R.6
McNair, L.7
Alam, J.8
Muir, A.J.9
-
48
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
10.1056/NEJMoa1012912. 21696307
-
Telaprevir for previously untreated chronic hepatitis C virus infection. Jacobson IM McHutchison JG Dusheiko G Di Bisceglie AM, Reddy KR Bzowej NH, Marcellin P Muir AJ, Ferenci P Flisiak R, George J Rizzetto M, Shouval D Sola R, Terg RA Yoshida EM, Adda N Bengtsson L, Sankoh AJ Kieffer TL, George S Kauffman RS, Zeuzem S,, N Engl J Med 2011 364 2405 2416 10.1056/NEJMoa1012912 21696307
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
Di Bisceglie, A.M.4
Reddy, K.R.5
Bzowej, N.H.6
Marcellin, P.7
Muir, A.J.8
Ferenci, P.9
Flisiak, R.10
George, J.11
Rizzetto, M.12
Shouval, D.13
Sola, R.14
Terg, R.A.15
Yoshida, E.M.16
Adda, N.17
Bengtsson, L.18
Sankoh, A.J.19
Kieffer, T.L.20
George, S.21
Kauffman, R.S.22
Zeuzem, S.23
more..
-
49
-
-
59749090086
-
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034)
-
10.1128/AAC.01081-08. 18936191
-
Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Flint M Mullen S Deatly AM Chen W, Miller LZ Ralston R, Broom C Emini EA, Howe AY,, Antimicrob Agents Chemother 2009 53 401 411 10.1128/AAC.01081-08 18936191
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 401-411
-
-
Flint, M.1
Mullen, S.2
Deatly, A.M.3
Chen, W.4
Miller, L.Z.5
Ralston, R.6
Broom, C.7
Emini, E.A.8
Howe, A.Y.9
-
50
-
-
33644639990
-
SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells
-
DOI 10.1128/AAC.50.3.1013-1020.2006
-
SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Malcolm BA Liu R, Lahser F Agrawal S, Belanger B Butkiewicz N, Chase R Gheyas F, Hart A Hesk D, Ingravallo P Jiang C, Kong R Lu J, Pichardo J Prongay A, Skelton A Tong X, Venkatraman S Xia E, Girijavallabhan V Njoroge FG, Antimicrob Agents Chemother 2006 50 1013 1020 10.1128/AAC.50.3.1013-1020.2006 16495264 (Pubitemid 43327807)
-
(2006)
Antimicrobial Agents and Chemotherapy
, vol.50
, Issue.3
, pp. 1013-1020
-
-
Malcolm, B.A.1
Liu, R.2
Lahser, F.3
Agrawal, S.4
Belanger, B.5
Butkiewicz, N.6
Chase, R.7
Gheyas, F.8
Hart, A.9
Hesk, D.10
Ingravallo, P.11
Jiang, C.12
Kong, R.13
Lu, J.14
Pichardo, J.15
Prongay, A.16
Skelton, A.17
Tong, X.18
Venkatraman, S.19
Xia, E.20
Girijavallabhan, V.21
Njoroge, F.G.22
more..
-
51
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
10.1056/NEJMoa1009482. 21449784
-
Boceprevir for previously treated chronic HCV genotype 1 infection. Bacon BR Gordon SC, Lawitz E Marcellin P, Vierling JM Zeuzem S, Poordad F Goodman ZD, Sings HL Boparai N, Burroughs M Brass CA, Albrecht JK Esteban R, N Engl J Med 2011 364 1207 1217 10.1056/NEJMoa1009482 21449784
-
(2011)
N Engl J Med
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
Marcellin, P.4
Vierling, J.M.5
Zeuzem, S.6
Poordad, F.7
Goodman, Z.D.8
Sings, H.L.9
Boparai, N.10
Burroughs, M.11
Brass, C.A.12
Albrecht, J.K.13
Esteban, R.14
-
52
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
10.1056/NEJMoa1010494. 21449783
-
Boceprevir for untreated chronic HCV genotype 1 infection. Poordad F McCone J Jr Bacon BR Bruno S, Manns MP Sulkowski MS, Jacobson IM Reddy KR, Goodman ZD Boparai N, DiNubile MJ Sniukiene V, Brass CA Albrecht JK, Bronowicki JP,, N Engl J Med 2011 364 1195 1206 10.1056/NEJMoa1010494 21449783
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone, Jr.J.2
Bacon, B.R.3
Bruno, S.4
Manns, M.P.5
Sulkowski, M.S.6
Jacobson, I.M.7
Reddy, K.R.8
Goodman, Z.D.9
Boparai, N.10
Dinubile, M.J.11
Sniukiene, V.12
Brass, C.A.13
Albrecht, J.K.14
Bronowicki, J.P.15
-
53
-
-
84859780819
-
Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: Pre-existing resistant variants and dynamics of resistant populations
-
Berlin, Germany. 22139868
-
Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: pre-existing resistant variants and dynamics of resistant populations. Chevaliez S Rodriguez C, Soulier A Ahmed-Belkacem A, Hezode C Pawlotsky JM, The International Liver Congress 2011 by EASL (46th annual meeting) Berlin, Germany 2011 22139868
-
(2011)
The International Liver Congress 2011 by EASL (46th Annual Meeting)
-
-
Chevaliez, S.1
Rodriguez, C.2
Soulier, A.3
Ahmed-Belkacem, A.4
Hezode, C.5
Pawlotsky, J.M.6
-
55
-
-
84890455968
-
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
-
Berlin, Germany. 22139868
-
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials. Sullivan JC De Meyer S Bartels DJ Dierynck I, Zhang E Spanks J, Tigges A Adda N, Martin EC Beumont M, Jacobson IM Sherman KE, Zeuzem S Picchio G, Kieffer TL,, The International Liver Congress 2011 by EASL (46th annual meeting) Berlin, Germany 2011 22139868
-
(2011)
The International Liver Congress 2011 by EASL (46th Annual Meeting)
-
-
Sullivan, J.C.1
De Meyer, S.2
Bartels, D.J.3
Dierynck, I.4
Zhang, E.5
Spanks, J.6
Tigges, A.7
Adda, N.8
Martin, E.C.9
Beumont, M.10
Jacobson, I.M.11
Sherman, K.E.12
Zeuzem, S.13
Picchio, G.14
Kieffer, T.L.15
-
56
-
-
23944482649
-
Challenges and successes in developing new therapies for hepatitis C
-
DOI 10.1038/nature04080
-
Challenges and successes in developing new therapies for hepatitis C. De Francesco R Migliaccio G, Nature 2005 436 953 960 10.1038/nature04080 16107835 (Pubitemid 41191671)
-
(2005)
Nature
, vol.436
, Issue.7053
, pp. 953-960
-
-
De Francesco, R.1
Migliaccio, G.2
-
57
-
-
14644389360
-
Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin
-
DOI 10.1055/s-2005-864780
-
Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin. Brau N, Semin Liver Dis 2005 25 33 51 10.1055/s-2005-864780 15731996 (Pubitemid 40322349)
-
(2005)
Seminars in Liver Disease
, vol.25
, Issue.1
, pp. 33-51
-
-
Brau, N.1
-
58
-
-
79953870639
-
Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007
-
10.1111/j.1365-2893.2010.01299.x. 20367803
-
Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007. Vellozzi C Buchacz K, Baker R Spradling PR, Richardson J Moorman A, Tedaldi E Durham M, Ward J Brooks JT, J Viral Hepat 2011 18 316 324 10.1111/j.1365-2893.2010.01299.x 20367803
-
(2011)
J Viral Hepat
, vol.18
, pp. 316-324
-
-
Vellozzi, C.1
Buchacz, K.2
Baker, R.3
Spradling, P.R.4
Richardson, J.5
Moorman, A.6
Tedaldi, E.7
Durham, M.8
Ward, J.9
Brooks, J.T.10
-
60
-
-
80053339008
-
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases
-
10.1002/hep.24641. 21898493
-
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases. Ghany MG Nelson DR Strader DB Thomas DL, Seeff LB,, Hepatology 2011 54 1433 1444 10.1002/hep.24641 21898493
-
(2011)
Hepatology
, vol.54
, pp. 1433-1444
-
-
Ghany, M.G.1
Nelson, D.R.2
Strader, D.B.3
Thomas, D.L.4
Seeff, L.B.5
-
61
-
-
36749001029
-
The way forward in HCV treatment - Finding the right path
-
DOI 10.1038/nrd2411, PII NRD2411
-
The way forward in HCV treatment-finding the right path. Manns MP Foster GR, Rockstroh JK Zeuzem S, Zoulim F Houghton M, Nat Rev Drug Discov 2007 6 991 1000 10.1038/nrd2411 18049473 (Pubitemid 350201789)
-
(2007)
Nature Reviews Drug Discovery
, vol.6
, Issue.12
, pp. 991-1000
-
-
Manns, M.P.1
Foster, G.R.2
Rockstroh, J.K.3
Zeuzem, S.4
Zoulim, F.5
Houghton, M.6
-
62
-
-
0038352047
-
Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population
-
DOI 10.1001/jama.290.2.228
-
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. Salomon JA Weinstein MC, Hammitt JK Goldie SJ, JAMA 2003 290 228 237 10.1001/jama.290.2.228 12851278 (Pubitemid 37430062)
-
(2003)
Journal of the American Medical Association
, vol.290
, Issue.2
, pp. 228-237
-
-
Salomon, J.A.1
Weinstein, M.C.2
Hammitt, J.K.3
Goldie, S.J.4
-
63
-
-
13644267743
-
Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security
-
Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Siebert U Sroczynski G, Int J Technol Assess Health Care 2005 21 55 65 15736515 (Pubitemid 40229369)
-
(2005)
International Journal of Technology Assessment in Health Care
, vol.21
, Issue.1
, pp. 55-65
-
-
Siebert, U.1
Sroczynski, G.2
-
64
-
-
33745696443
-
Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C
-
16194133
-
Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. Malone DC Tran TT Poordad FF,, J Manag Care Pharm 2005 11 687 694 16194133
-
(2005)
J Manag Care Pharm
, vol.11
, pp. 687-694
-
-
Malone, D.C.1
Tran, T.T.2
Poordad, F.F.3
-
65
-
-
79952233518
-
Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States
-
10.1002/hep.24131. 21319199
-
Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Stepanova M Kanwal F, El-Serag HB Younossi ZM, Hepatology 2011 53 737 745 10.1002/hep.24131 21319199
-
(2011)
Hepatology
, vol.53
, pp. 737-745
-
-
Stepanova, M.1
Kanwal, F.2
El-Serag, H.B.3
Younossi, Z.M.4
-
66
-
-
21244433445
-
Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase
-
DOI 10.1016/j.molcel.2005.05.014, PII S1097276505013201
-
Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Watashi K Ishii N Hijikata M Inoue D, Murata T Miyanari Y, Shimotohno K,, Mol Cell 2005 19 111 122 10.1016/j.molcel.2005.05.014 15989969 (Pubitemid 40884662)
-
(2005)
Molecular Cell
, vol.19
, Issue.1
, pp. 111-122
-
-
Watashi, K.1
Ishii, N.2
Hijikata, M.3
Inoue, D.4
Murata, T.5
Miyanari, Y.6
Shimotohno, K.7
-
67
-
-
62949181285
-
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors
-
10.1128/AAC.00939-08. 19104013
-
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Coelmont L Kaptein S Paeshuyse J Vliegen I, Dumont JM Vuagniaux G, Neyts J,, Antimicrob Agents Chemother 2009 53 967 976 10.1128/AAC.00939-08 19104013
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 967-976
-
-
Coelmont, L.1
Kaptein, S.2
Paeshuyse, J.3
Vliegen, I.4
Dumont, J.M.5
Vuagniaux, G.6
Neyts, J.7
-
68
-
-
75749110945
-
SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro
-
19933795
-
SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Hopkins S Huang Z Murray MG Wring S, Smitley C Harris R, Erdmann F Fischer G, Ribeill Y,, Antimicrob Agents Chemother 2009 54 660 672 19933795
-
(2009)
Antimicrob Agents Chemother
, vol.54
, pp. 660-672
-
-
Hopkins, S.1
Huang, Z.2
Murray, M.G.3
Wring, S.4
Smitley, C.5
Harris, R.6
Erdmann, F.7
Fischer, G.8
Ribeill, Y.9
-
69
-
-
36348931521
-
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus
-
DOI 10.1002/hep.21773
-
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. McHutchison JG Bacon BR Gordon SC Lawitz E, Shiffman M Afdhal NH, Jacobson IM Muir A, Al-Adhami M Morris ML, Lekstrom-Himes JA Efler SM, Davis HL,, Hepatology 2007 46 1341 1349 10.1002/hep.21773 17929306 (Pubitemid 350155515)
-
(2007)
Hepatology
, vol.46
, Issue.5
, pp. 1341-1349
-
-
McHutchison, J.G.1
Bacon, B.R.2
Gordon, S.C.3
Lawitz, E.4
Shiffman, M.5
Afdhal, N.H.6
Jacobson, I.M.7
Muir, A.8
Al-Adhami, M.9
Morris, M.L.10
Lekstrom-Himes, J.A.11
Efler, S.M.12
Davis, H.L.13
-
70
-
-
24144448068
-
Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection
-
DOI 10.1002/hep.20839
-
Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Horsmans Y Berg T, Desager JP Mueller T, Schott E Fletcher SP, Steffy KR Bauman LA, Kerr BM Averett DR, Hepatology 2005 42 724 731 10.1002/hep.20839 16116638 (Pubitemid 41233667)
-
(2005)
Hepatology
, vol.42
, Issue.3
, pp. 724-731
-
-
Horsmans, Y.1
Berg, T.2
Desager, J.-P.3
Mueller, T.4
Schott, E.5
Fletcher, S.P.6
Steffy, K.R.7
Bauman, L.A.8
Kerr, B.M.9
Averett, D.R.10
-
71
-
-
67651251216
-
Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides
-
10.3748/wjg.15.1805. 19370775
-
Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. Keeffe EB Rossignol JF, World J Gastroenterol 2009 15 1805 1808 10.3748/wjg.15.1805 19370775
-
(2009)
World J Gastroenterol
, vol.15
, pp. 1805-1808
-
-
Keeffe, E.B.1
Rossignol, J.F.2
-
72
-
-
48449084880
-
Clinical trial: Randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4
-
10.1111/j.1365-2036.2008.03781.x. 18616643
-
Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Rossignol JF Kabil SM El-Gohary Y Elfert A, Keeffe EB,, Aliment Pharmacol Ther 2008 28 574 580 10.1111/j.1365-2036.2008.03781.x 18616643
-
(2008)
Aliment Pharmacol Ther
, vol.28
, pp. 574-580
-
-
Rossignol, J.F.1
Kabil, S.M.2
El-Gohary, Y.3
Elfert, A.4
Keeffe, E.B.5
-
73
-
-
37449014458
-
Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication
-
10.1016/j.antiviral.2007.08.005. 17888524
-
Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Korba BE Montero AB Farrar K Gaye K, Mukerjee S Ayers MS, Rossignol JF,, Antiviral Res 2008 77 56 63 10.1016/j.antiviral.2007.08.005 17888524
-
(2008)
Antiviral Res
, vol.77
, pp. 56-63
-
-
Korba, B.E.1
Montero, A.B.2
Farrar, K.3
Gaye, K.4
Mukerjee, S.5
Ayers, M.S.6
Rossignol, J.F.7
-
74
-
-
34347213785
-
Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees
-
DOI 10.1073/pnas.0702162104
-
Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Elmowalid GA Qiao M Jeong SH Borg BB, Baumert TF Sapp RK, Hu Z Murthy K, Liang TJ,, Proc Natl Acad Sci USA 2007 104 8427 8432 10.1073/pnas.0702162104 17485666 (Pubitemid 47175504)
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, Issue.20
, pp. 8427-8432
-
-
Elmowalid, G.A.1
Qiao, M.2
Jeong, S.-H.3
Borg, B.B.4
Baumert, T.F.5
Sapp, R.K.6
Hu, Z.7
Murthy, K.8
Liang, T.J.9
-
75
-
-
2942643933
-
Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates
-
DOI 10.1128/JVI.78.13.6995-7003.2004
-
Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. Jeong SH Qiao M Nascimbeni M Hu Z, Rehermann B Murthy K, Liang TJ,, J Virol 2004 78 6995 7003 10.1128/JVI.78.13.6995-7003.2004 15194776 (Pubitemid 38781538)
-
(2004)
Journal of Virology
, vol.78
, Issue.13
, pp. 6995-7003
-
-
Jeong, S.-H.1
Qiao, M.2
Nascimbeni, M.3
Hu, Z.4
Rehermann, B.5
Murthy, K.6
Liang, T.J.7
-
76
-
-
32944465532
-
Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee
-
10.1002/hep.20934. 16317673
-
Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Youn JW Park SH Lavillette D Cosset FL, Yang SH Lee CG, Jin HT Kim CM, Shata MT Lee DH, Pfahler W Prince AM, Sung YC,, Hepatology 2005 42 1429 1436 10.1002/hep.20934 16317673
-
(2005)
Hepatology
, vol.42
, pp. 1429-1436
-
-
Youn, J.W.1
Park, S.H.2
Lavillette, D.3
Cosset, F.L.4
Yang, S.H.5
Lee, C.G.6
Jin, H.T.7
Kim, C.M.8
Shata, M.T.9
Lee, D.H.10
Pfahler, W.11
Prince, A.M.12
Sung, Y.C.13
-
77
-
-
37549014866
-
Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein
-
10.1038/sj.mt.6300333. 17923840
-
Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. Zabaleta A Llopiz D Arribillaga L Silva L, Riezu-Boj JI Lasarte JJ, Borras-Cuesta F Prieto J, Sarobe P,, Mol Ther 2008 16 210 217 10.1038/sj.mt.6300333 17923840
-
(2008)
Mol Ther
, vol.16
, pp. 210-217
-
-
Zabaleta, A.1
Llopiz, D.2
Arribillaga, L.3
Silva, L.4
Riezu-Boj, J.I.5
Lasarte, J.J.6
Borras-Cuesta, F.7
Prieto, J.8
Sarobe, P.9
-
78
-
-
30344446364
-
Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3
-
DOI 10.1099/vir.0.81423-0
-
Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3. Yu H Huang H Xiang J Babiuk LA, van Drunen Littel-van den Hurk S,, J Gen Virol 2006 87 1 10 10.1099/vir.0.81423-0 16361412 (Pubitemid 43056938)
-
(2006)
Journal of General Virology
, vol.87
, Issue.1
, pp. 1-10
-
-
Yu, H.1
Huang, H.2
Xiang, J.3
Babiuk, L.A.4
Van Drunen Littel-Van Den Hurk, S.5
-
79
-
-
67650523019
-
Hepatitis C virus infection and immunomodulatory therapies
-
10.1016/j.cld.2009.05.007. 19628156
-
Hepatitis C virus infection and immunomodulatory therapies. Forde KA Reddy KR, Clin Liver Dis 2009 13 391 401 10.1016/j.cld.2009.05.007 19628156
-
(2009)
Clin Liver Dis
, vol.13
, pp. 391-401
-
-
Forde, K.A.1
Reddy, K.R.2
-
81
-
-
84856159009
-
Preliminary study of two antiviral agents for hepatitis C genotype 1
-
10.1056/NEJMoa1104430. 22256805
-
Preliminary study of two antiviral agents for hepatitis C genotype 1. Lok AS Gardiner DF, Lawitz E Martorell C, Everson GT Ghalib R, Reindollar R Rustgi V, McPhee F Wind-Rotolo M, Persson A Zhu K, Dimitrova DI Eley T, Guo T Grasela DM, Pasquinelli C, N Engl J Med 2012 366 3 216 224 10.1056/NEJMoa1104430 22256805
-
(2012)
N Engl J Med
, vol.366
, Issue.3
, pp. 216-224
-
-
Lok, A.S.1
Gardiner, D.F.2
Lawitz, E.3
Martorell, C.4
Everson, G.T.5
Ghalib, R.6
Reindollar, R.7
Rustgi, V.8
McPhee, F.9
Wind-Rotolo, M.10
Persson, A.11
Zhu, K.12
Dimitrova, D.I.13
Eley, T.14
Guo, T.15
Grasela, D.M.16
Pasquinelli, C.17
|